The US FDA has approved Bristol Myers Squibb’s new oral medicine, Cobenfy, for treating schizophrenia in adults. This approval introduces a novel pharmacological approach after more than 30 years. The drug will be available by late October at $1,850 per month before insurance and rebates. Clinical trials have shown significant improvement in symptoms compared to a placebo.from Business News: Latest News on Business, Stock Markets, Financial News, India Business & World Business News https://ift.tt/xtbNSMX
https://ift.tt/leF4Z79
0 Comments